Relapse is a serious complication following high-dose therapy and autologous bone marrow transplantation (ABMT) for malignant lymphoma (ML). Allogeneic transplantation (alloSCT) is a therapeutic option. However, it is associated with a high incidence of transplantrelated organ toxicity and mortality. We recently reported fast engraftment and minimal transplantrelated toxicity, using fludarabine-based conditioning with reduced amounts of chemotoxic drugs prior to alloSCT. We now present our experience with 23 heavily treated high risk ML patients who underwent matched alloSCT following the same low intensity conditioning. The patients (20 male, three female) were aged 13-63 years. Nineteen had NHL and four HD (resistant disease 12, partial remission 11). Five were post ABMT. Twenty-two patients had fully matched sibling donors, and one a fully matched unrelated donor. Engraftment was fast. There was no rejection or nonengraftment. Organ toxicity was moderate with no liver or renal toxicity Ͼgrade II. Four patients developed Ͼgrade II graft-versus-host disease (GVHD). Seven patients died -four of grade III-IV GVHD and severe infections, two of bacterial sepsis, one of pulmonary failure. Ten patients are alive after 22.5 (15-37) months. Survival and disease-free survival at 37 months are both 40%. Probability of relapse is 26%. These encouraging results suggest that alloSCT following fludarabinebased low intensity conditioning in high-risk patients merits further evaluation. Bone Marrow Transplantation (2000) 25, 1021-1028. Keywords: allogeneic; peripheral blood stem cell transplantation; malignant lymphoma; fludarabine; low intensity conditioning regimen High-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (ASCT) has gained widespread acceptance as the treatment for aggressive nonHodgkin's lymphoma (NHL) in chemosensitive relapse,
and Hodgkin's disease (HD) that relapses after combination chemotherapy. [1] [2] [3] [4] However, the relapse rate following this procedure still remains high. [5] [6] [7] [8] Residual tumor cells resistant to high-dose chemoradiotherapy may be responsible for the relatively high rate of disease recurrence. It is believed that the high relapse rate of disease following ASCT is due to the lack of immune response of immunocompetent cells against residual tumor cells. 9, 10 We have previously shown, in a murine model of B cell lymphoma (BCL 1 ), that it is possible to induce a potent graft-versus-lymphoma (GVLy) effect by allogeneic, but not syngeneic, transplantation. 11 Subsequently, we were able to induce a GVLy effect in the same murine model by administration of allogeneic lymphocytes following transplantation. 12, 13 Recently, an allogeneic GVLy effect has been induced in malignant lymphoma (ML) patients by administration of donor lymphocyte infusion. [14] [15] [16] [17] It has also been demonstrated that it is possible to induce an immune mediated GVLy effect, in a manner similar to a graft-versus-leukemia effect, in certain categories of NHL patients who have undergone allogeneic bone marrow transplantation. 14, [18] [19] [20] [21] Allogeneic stem cell transplantation (alloSCT) is therefore a potential therapeutic option for advanced, high risk ML patients. However, especially in this category of patients, allogeneic bone marrow transplantation (alloBMT) is associated with a high frequency of transplant-related organ toxicity, morbidity and mortality. 17, 18, [22] [23] [24] [25] [26] [27] Fludarabine monophosphate (Fludara), the backbone of our low intensity conditioning regimen, is a chemotherapeutic drug that has been shown to inhibit DNA replication and repair effectively by binding and inhibiting DNA polymerase C, DNA primase and DNA ligase I, as well as by inhibiting RNA synthesis and inducing apoptosis of cells belonging predominantly to the lymphocytic series. [28] [29] [30] Fludara has been shown to be therapeutically efficacious against lymphoid malignancies. [31] [32] [33] [34] [35] [36] [37] In addition, it is an effective immunosuppressive drug 38, 39 especially in conjunction with anti-T lymphocyte globulin (ATG), 39, 40 and may possibly play a role in reducing the incidence and severity of graft-versus-host disease (GVHD). 41 We have recently demonstrated that it may be possible to achieve durable engraftment of donor hematopoietic stem cells while minimizing procedure-related toxicity using a low intensity conditioning regimen consisting of Fludara, busulfan (BU) and ATG prior to transplantation of granulocyte colony-stimulating factor (G-CSF)-mobilized allogeneic peripheral blood stem cells (alloSCT). 40 The aim of the current study was to use the Fludara-based low intensity conditioning protocol as a preparative regimen for alloSCT in advanced, heavily treated, high risk ML patients.
As will be shown below, our preliminary results on the use of this protocol in 23 consecutive high risk patients with advanced ML seem promising and suggest that the Fludara-based low intensity protocol may reduce organ toxicity and yet be adequate for early and durable engraftment of donor blood stem cells in ML patients.
Materials and methods

Patient characteristics, conditioning regimen and transplantation protocols
Twenty-three consecutive patients with malignant lymphomas were included in this study. Nineteen had NHL and four HD. Twenty were male and three female, of median age 41 (13-63) years. Their demographic and clinical characteristics, including disease staging and grading as well as previous chemotherapy or immunotherapy regimens, radiotherapy and status at alloSCT, are presented in Table 1 . Of the NHL patients seven had intermediate and 12 high grade ML (as defined by the International Working Formulation), 15 had stage IV, three stage III, and one stage II at presentation, and 10 had B symptoms. Three of the four HD patients had stage IVB and one stage IIIB at presentation. Their histology was nodular sclerosis (NS) three, and mixed cellularity (MC) one. Of the total 23 patients, 12 (52%) had resistant disease (primary refractory, or resistant relapse) and 11 (48%) were in second or third partial relapse (PR) at transplant. Five of the 23 patients were post ABMT. All of them had previously received multiple courses of chemotherapy, and 10 had received radiotherapy as well.
Engraftment
Engraftment was defined as a white blood cell count (WBC) of Ͼ1.0 × 10 9 /l with an absolute neutrophil count (ANC) of Ͼ0.5 × 10 9 /l for 3 consecutive days, and unsupported platelet counts of Ͼ25 × 10 9 /l. Chimerism was assessed by standard cytogenetic analysis in male/female recipient-donor combinations. In some of the patients BCL 2 was followed periodically by polymerase chain reaction (PCR). 42 Residual male cells in female to male chimeras were detected by the amelogenine gene method, as previously described. 43 In sex-matched recipient-donor combinations the variable number of tandem repeats (VNTR) PCR was used to document engraftment or residual host-type cells, with a 5% sensitivity of detection of residual host or donor cells. 44 
GVHD
GVHD was diagnosed and graded according to the Seattle criteria of clinical and pathological indices. 45, 46 A skin biopsy was obtained whenever required to confirm the diagnosis.
Graft rejection (GR)
GR was defined as peripheral blood aplasia and marrow hypoplasia Ͼ21 days after transplantation, with no evidence of donor markers revealed by cytogenetic and molecular techniques. 43, 44 Toxicity grading All non-hematologic organ dysfunction from day 0 to day +28 was considered as transplant-related toxicity (TRT) and graded according to the criteria of Bearman et al. 47 
Transplant-related mortality (TRM)
TRM was defined as such if death occurred from a cause related to the transplant procedure.
Statistical evaluation
The Kaplan-Meier method was used to calculate the probability of disease-free survival (DSF) as a function of time, as well as for determining the time to recovery of hematopoiesis.
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Results
Patients
The 23 patients in this study (NHL 19; HD four) were very high risk, and heavily treated. Twelve (52%) had resistant disease (primary refractory disease or resistant relapse) and 11 (48%) were in advanced PR (see Table 1 ). For five (22%) of the patients this was a second transplantation for relapsing lymphoma 7 (5-57) months following ABMT ( Table 1) . Two of the patients had anaplastic Ki-1 lymphoma. Five of the patients had lung involvement, two CNS involvement and two had bone involvement at the time of alloSCT ( Table 1) . One of the patients (UPN 488) was transplanted for secondary NHL following ABMT for HD. The patients had all received multiple courses of chemotherapy with multiple drug combinations (median 3 (2-6) chemotherapy protocols) pre-alloSCT, and 10 (43%) had also received radiotherapy (Table 1) .
Engraftment and chimerism
All 23 patients engrafted. There was no early or late graft failure. In seven patients the ANC did not fall below 0.2 × 10 9 /l throughout the alloSCT procedure. In the remaining 16 patients it took a median of 7 (range 4-10) days for the ANC to drop below 0.1 × 10 9 /l. In all patients the platelet counts decreased to Ͻ20 × 10 9 /l within a median of 7 (range 4-10) days, and all required platelet support. Table 1 ) did not have platelet engraftment. He developed severe resistant thrombocytopenia and sepsis, and died 2 months post alloSCT. Of the 23 patients, 16 (70%) had full donor chimerism while seven (30%) had mixed chimerism according to either the amelogenine gene or the VNTR PCR techniques, which were performed on the day of engraftment and every month subsequently.
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Transplant-related organ toxicity
Transplant-related organ toxicity was quite moderate in these previously very heavily treated patients. As can be seen in Table 2 , we observed only four cases with Ͼgrade II toxicity, according to the Bearman scale. 47 One patient (UPN 1214), who received mantle radiotherapy 2 months prior to alloSCT, developed grade IV pulmonary toxicity and failure necessitating intubation and mechanical ventilation, which eventually resulted in death 2 months post alloSCT. One patient (UPN 1166) with resistant NHL developed grade III renal toxicity due to Pseudomonas aeruginosa sepsis, and died 2 months post alloSCT. An additional two patients, one (UPN 482) who underwent alloSCT for relapsing NHL post-ABMT, and the other (UPN 1274) with resistant NHL with CNS involvement, developed grade III neurotoxicity manifested by progressive myelopathy and paraparesis. Both these patients had received radiotherapy involving the spinal cord prior to alloSCT. While no definite conclusion could be reached as to the cause of this complication, Fludara cannot be ruled out as a contributing factor.
Grade II mucositis was documented in 10 (43%) of the patients. All patients maintained some oral intake throughout the procedure, with 10 (43%) never requiring any parenteral caloric supplements. None of the patients developed severe veno-occlusive disease (VOD) of the liver. Mild to moderate (grade I-II) transient abnormal liver or renal function tests were observed in nine (39%) and eight (35%) patients, respectively ( Table 2 ). Four patients (17%) developed bacterial sepsis due to Pseudomonas aeruginosa, and died 2-4 months post alloSCT. Two of these also had grade III-IV GVHD, and in the other two the sepsis manifested as pneumonia and multiorgan failure. Two additional patients developed local infections, one due to Pseudomonas aeruginosa which manifested as septic arthritis, and the other due to E. coli as well as Klebsiella pneumoniae which manifested as skin abscesses. A further 11 patients had positive blood cultures for Staphylococcus coagulase. Four patients had positive PCR for cytomegalovirus (CMV) but no signs of CMV disease. Two patients with GVHD developed invasive fungal infections -one mucormycosis and the other aspergillosis -in the maxillary sinuses and lung, and died. An additional patient developed candidemia (Candida albicans) which responded to amphotericin therapy.
GVHD
Acute GVHD (aGVHD) Ͼgrade II was observed in four patients (grade IV two, involving skin and liver, and skin and gastrointestinal tract, respectively; grade III two, involving mainly skin). An additional four patients had grade II aGVHD involving the skin and liver, which responded to standard treatment with corticosteroids and cyclosporin A (CsA). All the patients were given CsA only as GVHD prophylaxis, and all the cases of aGVHD developed while the patients were on CsA. No further prophylactic therapy was added in an attempt to consolidate the GVLy effect in these patients with very aggressive and advanced ML. All four patients with grade III-IV aGVHD died of infectious complications -one of invasive mucormycosis, one of invasive aspergillosis, and two of Pseudomonas aeruginosa-induced sepsis.
Two patients progressed from acute to limited chronic GVHD (cGVHD). Two additional patients (UPN 488 and UPN 1098) developed cGVHD after receiving donor lymphocyte infusions (DLI) for minimal residual disease (MRD) post alloSCT. The cGVHD of UPN 488 (who suffered from secondary NHL 5 years after ABMT for HD) was extensive with involvement of the skin, mucosa, cornea and synovia. Immunosuppressive therapy achieved partial improvement, and the patient is currently 27 months post alloSCT, with no evidence of his secondary NHL. In patient UPN 1098 (who had NHL with mantle neuropathy) the cGVHD was transient, with limited involvement of the skin and mucosa. He responded to immunosuppressive therapy and is currently 34 months post alloSCT with no evidence of his NHL. His BCL 2 by PCR is negative.
Relapse/Progression of disease
Six patients (UPNs 482, 1260, 1274, 1290 with NHL, and UPNs 1192, 1249 with HD) suffered overt relapse or progressive disease 3.5 (1-8) months post alloSCT, and died 6 (2-13) months post alloSCT. Five of these patients had resistant disease and for three of them alloSCT was their second transplant. Four of the six patients achieved 100% donor chimerism, while two had mixed chimerism, according to amelogenine gene or VNTR PCR. In four of these patients (NHL three; HD one) an attempt was made to intensify the GVLy effect by discontinuation of CsA and administration of DLI, as previously published by us. 16, 20, 21, 49 They received up to 2.8 × 10 7 donor peripheral blood lymphocytes (PBL), but did not respond. An additional two patients with NHL received DLI for persistence of MRD post alloSCT. One of these (UPN 488), with secondary NHL of the lung post ABMT for HD, received three doses of donor PBL (1 × 10 5 , 1 × 10 6 and 1 × 10 7 /kg), the first dose 4 months post alloSCT and 1 month after discontinuation of CsA, with a 1 month break between doses. He responded with complete elimination of the pulmonary lesion. Subsequently, this patient developed extensive cGVHD as described above. The second patient (UPN 1098), with mantle neuropathy pre alloSCT and positive BCL 2 , received 2.43 × 10 7 PBL/kg 4 months post alloSCT. He responded with clearance of the BCL 2 (by PCR), developed transient limited cGVHD, and is currently 34 months post alloSCT, tumor-free, and with 100% donor chimerism by amelogenine gene PCR.
Cause of death
Four patients (17%) died of grade III-IV acute GVHD 6 (4-8) months post alloSCT, two of them with invasive fungi (mucormycosis and aspergillosis) and two with Pseudomonas aeruginosa sepsis. Two additional patients (9%) died of Pseudomonas aeruginosa sepsis and multiorgan failure 2 months following alloSCT. Only one patient (4%) died of transplant-related organ toxicity (grade IV pulmonary toxicity) 2 months after transplantation. Six patients (26%) died of relapse 6 (2-13) months post transplantation (Figure 2 ).
Survival and disease-free survival (DFS)
The Kaplan-Meier actuarial survival and DFS rates at 37 months were both 40% (95% confidence interval 18-65%). To date, after an observation period of 22.5 (range 15-37) months, 10 (43%) of our 23 very high risk malignant lymphoma patients treated with alloSCT following Fludarabased low intensity conditioning, are alive and disease free.
Bone Marrow Transplantation Kaplan-Meier actuarial probability of survival (a), disease-free survival (b), and probability of relapse (c) at 37 months of the entire group of 23 patients treated with alloSCT following low intensity conditioning.
Discussion
Our study suggests that durable and stable engraftment of donor hematopoietic cells may be accomplished in heavily treated advanced ML patients by a Fludara-based low intensity conditioning regimen followed by alloSCT. Since the chemotherapy in this novel conditioning is of relatively low intensity (4 mg/kg BU × 2 doses, or 60 mg/kg CTX × 2 doses), it is conceivable that the factor mainly responsible for engraftment is the immunosuppression induced by Fludara in conjunction with ATG, combined with the relatively high number of CD34 + cells in the peripheral blood infused at transplantation. Fludara is an effective immunosuppressive drug 38 that has been shown to synergize with ATG in promoting engraftment of megadose T cell-depleted CD34 + purified haploidentical alloSC across major HLA barriers. 39 It seems, therefore, that maximizing transient peri-transplant immunosuppression with the combination of Fludara and ATG on the one hand, and retaining donor alloreactive T cells on the other, while avoiding high doses of conventional myeloablative chemotherapy and intensive posttransplant immunosuppression, suffices to ensure stable engraftment and elimination of residual hematopoietic cells of host origin while minimizing organ toxicity. This observation is in agreement with previously published data, suggesting that donor immunocompetent lymphocytes can effectively displace host-derived hematopoietic cells. 49 Indeed, Nilsson et al 50 and Rao et al 51 have already documented the feasibility of achieving BM cell engraftment following syngeneic BMT with the establishment of mixed chimerism in non-myeloablated mice, when no transplantation barriers exist at all. Similarly, we and others have recently reported that it is possible to achieve stable and durable engraftment in patients with myeloid and lymphatic leukemias by intensive immunosuppression and minimal myeloablation. 40, 52, 53, 54 In the present study, we have observed 40% DFS at 37 months in a cohort of very high risk advanced malignant lymphoma patients, 52% of whom had resistant disease (22% following ABMT), 43% with prior radiotherapy, and all of them with multiple drug regimens and several courses of chemotherapy prior to alloSCT. According to a number of previous studies, patients with aggressive NHL and HD have an overall disease-free survival rate of 17-23%. [22] [23] [24] [25] [26] [27] 55 Many publications have dealt with the option of using allogeneic BMT, which offers the possibility of GVLy for relapsing or refractory malignant lymphoma. [20] [21] [22] [23] [24] [25] [26] We and others have used the allogeneic effect introduced by DLI for patients with lymphoma who relapsed following ABMT or who developed EBV lymphoma post transplantation.
14,15-17 Recent publications by Sykes et al state that it is possible to achieve a potent GVLy effect by using HLA-mismatched bone marrow cells, 56, 57 indicating that MHC disparate BM transplants can mediate an antitumor effect which greatly exceeds that achieved with MHC matched BMT. 58, 59 However, alloBMT in malignant lymphoma poses an increased risk of transplant-related complications, organ toxicity, GVHD and death, partially due to the myeloablative chemotherapy generally used in the preparative regimen. [20] [21] [22] [23] [24] [25] [26] [27] One of the traditional ways of overcoming some of these obstacles was to perform T cell depletion in conjunction with intensification of the preparative conditioning regimen by administration of total body irradiation (TBI) in order to ensure engraftment. 55, 60 By doing so it was possible to increase DFS to 44% while reducing acute and chronic GVHD to 36% and 12%, respectively. 55, 60 The approach that we have taken is to reduce the intensity of the conditioning in order to reduce transplant-related organ toxicity and mortality while sparing the GVLy effect, in the same way as we and others, did for leukemic patients. 40, [52] [53] [54] By doing so, we have, indeed, been able to reduce transplant-related organ toxicity. 21, 27 The recently reported HLA mismatched BMT in five patients with refractory NHL mentioned above 56, 57 were made possible by a similar approach, with a low intensity conditioning protocol comprising CTX, ATG and thymic irradiation. 56, 57 We reasoned that low intensity conditioning in conjunction with maximum transient immunosuppression induced by Fludara/ATG, enabled the large number of donorderived immunocompetent T lymphocytes given together with the donor's stem cells to mediate a GVLy effect which could further be amplified post alloSCT, on an outpatient basis, by allogeneic cell therapy with DLI, as previously published by us and others. [14] [15] [16] [17] Indeed, two of our current patients with persistent disease post alloSCT, responded to DLI.
Due to the short observation period and the small number of patients, our data must be carefully evaluated with no over-interpretation. Nonetheless, our results in this group of very high risk, heavily treated ML patients, are encouraging. The use of low intensity conditioning may, in the future, make it possible to achieve stable and durable engraftment, with complete or partial donor chimerism in this setting, while reducing the incidence of some of the existing complications, such as procedure-related organ toxicity. Our preliminary results should therefore be confirmed in a larger group of patients with longer follow-up.
